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Dear Editor
Exanthem with Cryopyrin Associated
Periodic Syndromes and
Consideration of IL-1 Targeted Therapy
for Neutrophilic Predominant Urticaria
The article by Kambe et al.1 is an excellent review on
the potential role of the inflammasome in skin disor-
ders. As one of the investigators involved in the dis-
covery of the cryopyrin mutation, I felt compelled to
comment on the exanthem associated with cryopyrin-
associated periodic syndromes (CAPS), i.e. Familial
Cold Auto-Inflammatory Syndrome, Muckle-Wells
Syndrome, and Neonatal Onset Multi-System Inflam-
matory Disorder, referred to as NOMID. This exan-
them is not true urticaria2 as: (1) it is erythematous,
macular-papular; (2) it is non-pruritic; (3) it can re-
main in situ for more than 24 hours; (4) it has dermal
infiltration primarily with neutrophils; (5) it has no
histo-pathological evidence of mast cell degranula-
tion; and (6) it is non-responsive to anti-histamines. I
suggest that typical urticaria is not a manifestation of
CAPS, and in lieu of this terminology, I would recom-
mend use of nomenclature, such as macular-papular
exanthem or urticaria-like exanthem, to differentiate
from true urticaria associated with vasoactive media-
tor release secondary to mast cell degranulation.
The authors make an important commentary that
the cytoplasm of mast cells contain the NLRP-3 in-
flammasome. The NLRP-3 inflammasome can be
stimulated by pathogen-associated molecular patterns
(PAMPs) and danger associated membrane patterns
(DAMPs), such as urate crystal formation, free ATP,
hypokalemia that can develop from catabolic tissue
injury. PAMPs and DAMPs can in turn stimulate a
cascade of events leading to extracellular secretion of
IL-1 cytokines. These cytokines can cause neutro-
philic chemotaxis by various immune pathways3 that
could explain skin biopsy proven perivascular neutro-
philic predominant urticaria, as described by Tharp.4
This particular type of urticaria is often less respon-
sive to anti-histamines. Assuming the inflammasome
is involved, there may be rationale to consider IL-1
targeted therapy in conjunction with optimal antihis-
tamine treatment for management of these condi-
tions. Moreover, clinicians frequently witness out-
breaks of urticaria in association with viral infections
and consequently this aforementioned inflammasome
mediated mechanism may explain some of the patho-
biology associated with infectious-induced urticaria.
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The Authors Respond
We appreciate the comments by Wanderer to our re-
cent review on the role of the NLRP3 inflammasome
in the pathogenesis of skin disorders,1 especially his
comments regarding the terminology of skin erup-
tion observed in cryopyrin-associated periodic syn-
drome (CAPS). We agree with his clarification that
examthema observed in CAPS is not true uticaria
(Fig. 1). As he pointed out, the eruption in CAPS is
an erythematous, non-pruritic rash that is not respon-
sive to antihistamines. Histopathologically the erup-
tion does not show evidence of mast cell degranula-
tion, rather infiltration of neutrophils without vasculi-
tis. In contrast, the eruption in CAPS patients disap-
pears without remaining pigmentation, suggesting
the absence of epidermal attack. Unlike typical urti-
caria, the molecular mechanism underlying CAPS is
based on mutation of the NLRP3 gene. Aberrant ac-
tivation of the NLRP3 inflammasome results in exces-
sive cleavage of pro-IL-1β and accumulation of active
IL-1β in dermal mast cells, a phenotype observed in
skin specimens from CAPS patients.2 Thus, the erup-
tion associated with CAPS varies both in genetic etiol-
ogy and histopathology from ordinary urticaria and
therefore may also be referred to as pseudourticaria.3
However, for us, as practicing dermatologists who
observe skin eruption at the bedside or the clinic, the
rash in CAPS still appears to visually resemble typical
urticaria. In the past, clinicians have classified the
eruption observed in familial cold autoinlammatory
syndrome (formerly known as familial cold urticaria)
and Muckle-Wells syndrome, both now recognized as
CAPS, as a form of urticaria, without knowledge of
the function of NLRP3. We believe that preserving
the classification of CAPS as a urticaria-like ex-
amthema will be beneficial to patients, their families
and some physicians who are not familiar with these
diseases. By retaining this classification system,
those interested in researching the characteristic
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Fig. 1 The urticaria-like exanthema in CAPS. The eruption 
is erythematous, non-pruritic rash that is not responsive to 
antihistamines.
autoinflammatory symptoms observed in CAPS, such
as skin rash, will be directed to the appropriate infor-
mation, thereby aiding in self or clinical diagnosis.
NLRP3 is the intracellular receptor for the molecu-
lar recognition of specific patterns associated with
pathogen or endogenous danger signals. We believe
that urticaria represents an essential host defense
mechanism, whereby the recognition of harmful
agents by NLRP3 evokes a urticarial reaction to wash
out unfavorable molecules to the lymphovessels
where specific immuno-corresponding cells lay in
wait. Therefore, we hope that further analysis of the
“urticaria-like exanthema” observed in CAPS, now
known to depend on the constitutively active status of
NLRP3 and resulting inflammasome activation, will
lead to a greater understanding of antihistamine re-
fractory urticaria.
We thank Dr. Aaron P. Burberry (The University of
Michigan) for English editing.
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